CIMG Inc. Reports 3,426% Revenue Growth but Faces Increased Net Loss in Latest 10-Q

CIMG Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenues of $2.17 million, a substantial increase from $61,578 in the same period last year, marking a growth of 3,426%. This surge in revenue is attributed to the successful sales of its Maca product line and the introduction of new offerings in the Homology of Medicine and Food Series, as well as the Computing Power Product Series. However, the cost of sales also rose sharply to $2.17 million from $56,445, leading to a gross profit of just $577, down 88.76% from $5,133 a year earlier.

CIMG's operating expenses decreased by 23.51% to $854,594 compared to $1.12 million in the previous year, primarily due to reduced sales and operational costs. Despite this reduction, the company reported a net loss of $10.5 million, a significant increase from a loss of $1.07 million in the prior year, largely driven by a decline in the fair value of its digital assets. For the nine months ending June 30, 2026, total revenue reached $21.16 million, a dramatic rise from $84,431 in the same period last year, while the net loss ballooned to $45.36 million from $2.99 million.

Operationally, CIMG has been undergoing a strategic transformation, shifting its focus from specialty coffee products to a broader range of health and wellness offerings, particularly in the Asian market. The company has expanded its product lines to include Maca-based dietary supplements and functional foods, as well as computing power products integrated with AI technology. This strategic pivot is supported by a digital marketing strategy aimed at enhancing customer engagement and sales.

As of June 30, 2026, CIMG's total assets were valued at approximately $69.07 million, down from $74.18 million a year prior. The company reported a significant decrease in cash reserves, with only $5,397 available compared to $137,287 in the previous year. The decline in cash and the substantial accumulated deficit of $132.59 million raise concerns about the company's ability to continue as a going concern. Management has indicated that it will need to secure additional funding to sustain operations, although there is no assurance that such financing will be available on favorable terms.

Looking ahead, CIMG's management remains focused on executing its revised business strategy and expanding its product offerings. The company is actively seeking additional capital through equity or debt financing to support its operations and growth initiatives. However, the ongoing challenges related to market conditions and the company's financial health may impact its ability to achieve these objectives.